



Published in final edited form as:

RSC Adv. 2014 January 1; 4(75): 39809–39816. doi:10.1039/C4RA08384A.

3-Substituted Biquinolinium Inhibitors of AraC Family Transcriptional Activator VirF from *S. flexneri* Obtained Through In Situ Chemical Ionization of 3,4-Disubstituted Dihydroquinolines

Prashi Jain^a, Jiaqin Li^b, Patrick Porubsky^a, Benjamin Neuenswander^c, Susan M. Egan^b,
Jeffrey Aubé^{a,c,d,e}, and Steven Rogers^d

^aCenter for Chemical Methodologies and Library Development, The University of Kansas, 2034
Becker Drive, Lawrence, Kansas, 66047, USA

^bDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS, USA

^cSpecialized Chemistry Center, The University of Kansas, 2034 Becker Drive, Lawrence, Kansas
66047, USA

^dUniversity of Kansas Center of Biomedical Research Excellence, Center for Cancer
Experimental Therapeutics, 2034 Becker Drive, Lawrence, KS, USA

^eDepartment of Medicinal Chemistry, University of Kansas, Lawrence, KS, USA

Abstract

During a structure–activity relationship optimization campaign to develop an inhibitor of AraC family transcriptional activators, we discovered an unexpected transformation of a previously reported inhibitor that occurs under the assay conditions. Once placed in the assay media, the 3, 4-disubstituted dihydroquinoline core of the active analogue rapidly undergoes a decomposition reaction to a quaternary 3-substituted biquinolinium. Further examination established an SAR for this chemotype while also demonstrating its resilience to irreversible binding of biologically relevant nucleophiles.

Introduction

The World Health Organization (WHO) recently published a warning that microbial resistance to antibiotics has become a “major threat to public health.”¹ A dearth of new FDA approved antimicrobial medicines coupled with the rapid development of resistance to available antibiotics is creating a health care void that necessitates the development of new antimicrobial strategies to combat microbial infectious disease.² One such strategy involves targeting non-growth essential virulence factors, which may avoid triggering resistance mechanism development by not placing selective pressure on microbes. As an example of

Correspondence to: Steven Rogers.

Supplementary data

Supplementary data (experimental protocols and structural characterization of target compounds) associated with this article can be found in the online version, at <http://>

this, the protein members of the AraC family of bacterial transcription activators activate expression of genes encoding virulence factors in various pathogenic bacteria such as *Vibrio cholerae* (ToxT),³ *enterotoxigenic Escherichia coli* (Rns/CfaD) (ETEC),⁴ *Pseudomonas aeruginosa* (ExsA)⁵ and *Shigella flexneri* (VirF)⁶, while other members of the family regulate bacterial stress responses or carbon metabolic operons.⁷ Furthermore, inhibition or deletion of AraC family activators has been demonstrated to ameliorate infections *in vitro* and in animal models.⁸

Our study focuses on VirF, an AraC family transcriptional activator from *Shigella flexneri*, the causative agent of bacillary dysentery, or shigellosis.⁹ This disease affects over 165 million people worldwide while leading to approximately 1.1 million deaths annually.¹⁰ VirF is necessary for the expression of virulence genes associated with the first step of *S. flexneri* pathogenesis, which is rectal, and colonic epithelial cell invasion as well as the subsequent cell-to-cell dissemination.¹¹ Using cell-based reporter gene assays with *S. flexneri* and *E. coli*, coupled with *in vitro* DNA-binding assays with purified VirF, we recently determined that **SE-1** (Figure 1) is an inhibitor of transcription activation and DNA binding by VirF.¹² Furthermore, through examining mRNA concentrations using real-time quantitative reverse transcription-PCR (qRT-PCR), it was found that **SE-1** reduced the expression of VirF-dependent virulence genes such as *icsS*, *icsB*, *ipaB*, and *virB* in *S. flexneri*. This initial study prompted us to seek analogues of **SE-1** with greater potency that could serve as a lead VirF inhibitor

In this manuscript, we detail our activity optimization efforts of **SE-1**¹², which was originally identified through screening of a commercially obtained small molecule library, and show that SE-1 and related analogues undergo ionization in aqueous medium to afford a quaternary 3-substituted biquinolinium salt (Figure 1). Although decomposition product is a synthetic precursor to the 3,4-disubstituted dihydroquinoline core, its ionization in biological media was unexpected. Thus, we present evidence here that the biquinolinium salt is the causative agent responsible for the observed inhibitory activity toward bacterial AraC family activators, discuss structure–activity relationships (SARs) associated with this chemotype, and demonstrate that it is stable in the presence of biologically relevant nucleophiles.

Results and Discussion

To gain preliminary SAR information to guide our synthetic endeavors, we procured and screened 24 commercially available analogues of **SE-1**, resulting in three compounds exhibiting notable activity in comparison to **SE-1** in the VirF *in vivo* dose-response assay in *E. coli* (Figure 2). The assays were performed as previously described.¹² Briefly, the analogues were dissolved in 100% dimethyl sulfoxide (DMSO). Bacterial cultures were grown to an optical density at 600 nm (OD₆₀₀) of ~0.1 and then mixed with various concentrations of analogues (final concentration of DMSO, 6.2%), induced with 1 mM IPTG (final concentration) for 3 hours at 37°C, lysed, and β-galactosidase activity was measured. Uninduced (no IPTG and no analogues) and uninhibited (1 mM IPTG and no analogues) controls were used to normalize β-galactosidase activity, as described previously.¹² To eliminate from consideration any analogues that nonspecifically inhibited β-galactosidase activity or cell growth, we also tested these analogues on a control strain that

carried a *lacZ* reporter fusion (*hts-lacZ*), with a synthetic promoter that was repressed by LacI and did not require VirF for activation, as described previously.¹² We found that analogues **E1**, **A2** and **C4** inhibited expression of the VirF-activated *virB-lacZ* fusion to the same extent as **SE-1**, with an IC₅₀ of 7 μM, 10 μM and 11 μM respectively. Other 4-substitutions were assessed such as an indole, a phenyl ring, a benzimidazole and a naphthyl ring in which all analogues were found to be inactive (Full list can be found in supplementary information). Analogues without N-substitution were also found to not exhibit activator inhibition.

To follow-up on our commercially accessible SAR, a series of 3, 4-disubstituted dihydroquinolines were synthesized as shown in scheme 1 that was adapted from protocols developed by Aksenov.¹³ We focused on the 4-methylnitro substitution instead of the malonic ester due to potential esterase liability and instead of the nitrile because **E1** was found to be more active than C4. Briefly, various aryl boronic acids were coupled via Suzuki reaction with 3-bromoquinolines through the treatment with bis(triphenylphosphine)palladium dichloride, potassium carbonate in a 4:1 mixture of dimethylformamide and water while heating to 150 °C for 30 minutes under microwave conditions. The resulting 3-substituted quinolines were subsequently *N*-substituted via electrophilic attack from various benzyl and alkyl halides, followed by a nucleophilic attack at the 4-position of the resulting quinolinium halide through the treatment with nitromethane under basic conditions in dioxane at room temperature, giving the desired 3,4-disubstituted dihydroquinolines. Both the 3,4-disubstituted dihydroquinolines and quinolinium halide synthetic intermediates were screened for inhibitory activity against VirF.

Initially, seven 3,4-disubstituted dihydroquinolines, three quinolinium synthetic precursors and a resynthesized **SE-1** (1) were synthesized and screened for VirF activator inhibition (Table 1). Replacing the *n*-butyl group with a 4-chlorobenzyl (5) resulted in a significant loss of activity against VirF activator inhibition. Replacing the quinoline with other aryl groups such as 5-methyl pyridine (6), 3-chlorophenyl (7) resulted in analogues with very modest inhibitory activity, giving IC₅₀ values >100 μM. Diminished activity was also observed when substituting the nitromethyl of the 1,4-dihydroquinoline with a phenyl (8) or methyl (11) as well in the same substitution of a 1,2-dihydroquinolines (entries 9 & 10). However, the resynthesized **SE-1** (Table 1) repeated the activity observed from the HTS sample with an IC₅₀ of 11 μM against VirF and >100 μM in the control strain.

As a first clue to the instability of these 1,4-dihydroquinoline cores, we observed that the quaternary amine quinolinium samples (Table 1., entries 2–4) exhibited the same, if not better activity against VirF while not affecting the control strain. This can be observed when comparing Table 1, entries 2 to **SE-1**(1), entries 3 to 5 and entries 4 to E1. Furthermore, the 3,4-disubstituted dihydroquinolines (Table 1, **SE-1** and entries 5–11) exhibited notable stability issues during their synthesis because they readily decomposed if purification attempts were made on normal phase chromatography with silica gel or reverse phase chromatography with C18-bonded silica gel. All 3,4-disubstituted dihydroquinolines had to be purified via recrystallization. We also noted that upon ¹H NMR analysis of various dihydroquinoline samples in DMSO-d₆ at room temperature two days after the samples had been prepared and analyzed, that a significant reversion to the quinolinium precursor was

observed. These observations prompted us to examine 1) the latent instability of **SE-1** and its analogues, 2) if the observed VirF inhibition activity was simply due to the quaternary species and 3) if non-quaternary adducts could be derived that demonstrated stability and VirF inhibitory activity.

To examine the aqueous stability of the 3,4-disubstituted dihydroquinoline analogues, samples were prepared at 10 μM in PBS at pH 7.4 (1% DMSO) and analyzed via auto-sampler by RP HPLC/UV/HRMS after the sample had been prepared and then every hour on the hour for 48 hours at room temperature. We found that **SE-1** had degraded completely to the corresponding quaternary salt by the 0th time point, or about 30 minutes elapsed time including assay preparation. Given that the VirF inhibition assays typically run 8–24 hours, the stability analysis predicted that no detectable concentration of the 3,4-disubstituted dihydroquinoline species was present during the assay and that the activity was simply due to the quinolinium salt. Since most quaternary ammonium salts have limited pharmaceutical relevance, save topical and oral hygiene applications due to their hemolytic nature,¹⁴ we began exploring non-quaternary analogues of our most potent VirF activator inhibitors.

The 3,4-disubstituted dihydroquinoline core was substituted with an indole (Table 2, entries 12 and 13), 9-acridone (15) and 4-quinolone (16), resulting in no inhibitory activity towards VirF or in the control strain assay. Interestingly, we also screened acridinium (14), pyridinium (17) and triethylammonium (18) salt analogues that would behave similarly to other cationic quaternary ammonium chemical detergents such as cetylpyridinium chloride (CPC) to compare the activity profiles to our more active quinolinium compounds. The triethylammonium analogue exhibited no inhibitory activity in our assays whereas the acridinium and pyridinium exhibited good to modest, non-specific activity against both the VirF and control strain, indicating that the activity we see with our quinolinium compounds is not simply due to detergent effects. This prompted us to continue optimizing the activity of the quinolinium core.

Various *N*-substituted and 3-aryl analogues were synthesized with aim to optimize the quinolinium core (Table 2, entries 19–24). As seen previously, *N*-substitution of *n*-butyl with methyl (4) gave decreased activity with a 90 μM IC₅₀ value, whereas *i*-propyl (19), *n*-propyl (20), *n*-hexyl (21) and pent-4-en-1-yl (24) all gave similar activity to **SE-1** with IC₅₀ values of 12 μM , 16 μM , 11 μM and 11 μM respectively, while not inhibiting the control strain. Replacing the 3-quinoline substituent with a naphthalene (23) was also well tolerated and gave an IC₅₀ value of 9 μM against VirF and >100 μM against the control strain, comparable activity to the parent compound (Table 1, entry 1). A modest increase in activity was attained while elongating the *N*-alkyl chain to *n*-nonyl (22); giving an IC₅₀ value of 3 μM against VirF, but notable selectivity was lost because of control strain inhibition with an IC₅₀ value of 25 μM . A planktonic bacterial growth curve analysis of both the VirF and control strains in the presence of Table 1, entry 6 demonstrated that this compound inhibited the growth of the bacteria, explaining the increase in activity against both strains. This toxic effect on bacterial growth was not seen with the other active compounds.

Given the inherent electrophilic nature of cationic species such quinoliniums, we assessed the stability of some of these analogues towards the thiol based nucleophiles dithiothreitol

and glutathione to mimic interactions with thiol containing amino acid residues of proteins in a biological system. Briefly, compounds were dissolved at 10 μM in PBS at pH 7.4 (1% DMSO) and incubated at room temperature with either no thiol source as a negative control, 50 μM glutathione (GSH). The mixtures were sampled every hour for eight hours for 48 hours and analyzed by RP HPLC/UV/HRMS. The masses of potential adducts were searched for in the final samples to determine if any detectable adduct formed. Ethacrynic acid, a known Michael acceptor, was used as a positive control. In both of the quinolinium salts assayed (entries 2 and 3), no GSH adducts were observed, suggesting these compounds to be relatively stable despite their expected reactivity, giving this chemotype possible application toward developing biological probes while suggesting that these inhibitors may not be acting in a covalent manner.

Conclusions

Through analysis of SAR data and chemical stability behavior, we have discovered that our previously reported 3,4-disubstituted dihydroquinoline inhibitor of AraC transcription activators,¹² readily fragments in assay media to a quinolinium core, which we ascribe as the active agent against this target. We note that **SE-1** and analogues are available from several commercial vendors; and the present results suggest that the ionized precursors may well be responsible for any observed biological activity for this chemotype. Although we did not increase VirF activator inhibition potency of this class of compounds, we expounded the SAR showed that the activity of the quinolinium analogues does depend on specific structure and was not due to generic detergent effects.

Experimental section

All air- and moisture-sensitive reactions were carried out in flame- or oven-dried glassware under argon atmosphere using standard gastight syringes, cannula, and septa. Stirring was achieved with oven-dried magnetic stir bars. Flash column chromatography was performed with SiO_2 from Sorbent Technology (30930M-25, Silica Gel 60A, 40–63 μm) or by using an automated chromatography instrument with an appropriately sized column. Thin layer chromatography was performed on silica gel w/UV254 plates (1624126, sorbent technologies). ^1H and ^{13}C NMR spectra were recorded on instruments operating at 400 or 500 MHz and 100 or 126 MHz respectively. High-resolution mass spectrometry (HRMS) spectra were obtained on an ESI-TOF mass spectrometer. The analytical method utilized a Waters Aquity BEH C18 column (2.1 \times 50 mm, 1.7 μm) eluting with a linear gradient of 95% water (modified to pH 9.8 through addition of NH_4OH) to 100% CH_3CN at 0.6 mL/min flow rate where purity was determined using UV peak area at 214 nm. Melting points were determined using an automated apparatus with digital imaging capability.

General procedure for 4-substituted biquinolines

To a solution of nitromethane (50 μL , 1.0 mmol) in THF (1 mL), solution of K_2CO_3 (21.8 mg, 0.15 mmol) in water (0.2 ml) was added gradually with stirring and the mixture was stirred for 5 mins. The 3-(2-quinolylyl)quinolinium halide (**1a–e**) (0.75 mmol) was added and the mixture stirred for 4 h at 23°C until a homogeneous solution was formed. The reaction was monitored by TLC/UPLC. The solution was poured into water (5 mL) and extracted

with ethyl acetate (3 × 5 mL). The organic layers were separated, combined, washed with brine, dried over Na₂SO₄, and evaporated *in vacuo*.

1-Butyl-4-(nitromethyl)-1,4'-dihydro-2,3-biquinoline (SE-1)

¹H NMR (400 MHz, Chloroform-*d*) δ 7.93 (dd, *J* = 8.4, 2.3 Hz, 2H), 7.65 (dd, *J* = 7.9, 1.4 Hz, 1H), 7.58 (ddd, *J* = 8.5, 6.9, 1.5 Hz, 1H), 7.49 (d, *J* = 8.8 Hz, 1H), 7.34 (ddd, *J* = 8.0, 6.9, 1.2 Hz, 1H), 7.29 (s, 1H), 7.24 – 7.21 (m, 1H), 7.21 – 7.18 (m, 1H), 6.96 (td, *J* = 7.4, 1.0 Hz, 1H), 6.88 (d, *J* = 8.5 Hz, 1H), 5.39 (dd, *J* = 8.2, 4.1 Hz, 1H), 4.70 (dd, *J* = 10.9, 4.1 Hz, 1H), 4.48 (dd, *J* = 10.9, 8.2 Hz, 1H), 3.79 (ddd, *J* = 14.4, 8.5, 5.9 Hz, 1H), 3.55 (ddd, *J* = 14.9, 8.5, 6.8 Hz, 1H), 1.72 (dq, *J* = 15.9, 7.8, 6.0 Hz, 2H), 1.39 (dtd, *J* = 15.1, 7.7, 6.0 Hz, 2H), 0.94 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (126 MHz, Acetone-*d*₆) δ 156.33, 148.99, 139.30, 138.15, 136.21, 130.09, 129.54, 128.90, 128.33, 127.10, 125.71, 123.31, 122.68, 117.46, 113.46, 106.43, 80.95, 51.29, 38.84, 30.90, 20.66, 14.14. HRMS (ESI) *m/z* calcd for C₂₃H₂₃N₃O₂ [M+H]⁺: 374.1824, found: 374.1856.

1-(4-chlorobenzyl)-4-(nitromethyl)-1,4-dihydro-2,3-biquinoline(5)

¹H NMR (400 MHz, Acetone-*d*₆) δ 8.16 (d, *J* = 9.0 Hz, 1H), 8.02 – 7.96 (m, 2H), 7.92 (d, *J* = 8.9 Hz, 1H), 7.85 (dd, *J* = 7.9, 1.4 Hz, 1H), 7.71 (ddd, *J* = 8.5, 6.9, 1.5 Hz, 1H), 7.50 – 7.35 (m, 6H), 7.21 – 7.15 (m, 1H), 7.04 (td, *J* = 7.5, 1.1 Hz, 1H), 6.95 (d, *J* = 8.1 Hz, 1H), 5.56 (dd, *J* = 7.7, 4.1 Hz, 1H), 5.26 – 5.08 (m, 2H), 4.93 (dd, *J* = 11.0, 4.1 Hz, 1H), 4.76 (dd, *J* = 11.0, 7.7 Hz, 1H). ¹³C NMR (126 MHz, Acetone-*d*₆) δ 156.24, 148.93, 139.33, 138.61, 137.70, 136.35, 133.42, 130.18, 130.17, 129.63, 129.60, 129.24, 128.83, 127.21, 125.92, 123.68, 122.70, 117.52, 114.23, 107.43, 81.31, 54.57, 38.69. HRMS (ESI) *m/z* calcd for C₂₆H₂₁ClN₃O₂ [M+H]⁺: 442.1244, found: 442.1288.

1-butyl-1,4-dihydro-[2,3-biquinoline]-4-carbonitrile (C1)

¹H NMR (400 MHz, Acetone-*d*₆) δ 8.17 (d, *J* = 8.7 Hz, 1H), 8.04 – 7.97 (m, 1H), 7.92 (d, *J* = 8.9 Hz, 1H), 7.90 (s, 1H), 7.86 (dd, *J* = 8.1, 1.5 Hz, 1H), 7.71 (ddd, *J* = 8.5, 6.9, 1.5 Hz, 1H), 7.61 (dd, *J* = 7.6, 1.5 Hz, 1H), 7.48 (ddd, *J* = 8.1, 6.9, 1.2 Hz, 1H), 7.40 (ddd, *J* = 8.6, 7.3, 1.6 Hz, 1H), 7.23 (d, *J* = 7.6 Hz, 1H), 7.16 (td, *J* = 7.5, 1.1 Hz, 1H), 5.92 (s, 1H), 4.12 – 4.00 (m, 1H), 3.91 (ddd, *J* = 14.9, 8.3, 6.9 Hz, 1H), 1.86 – 1.74 (m, 2H), 1.52 (dtd, *J* = 11.9, 7.3, 3.4 Hz, 2H), 1.01 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (100 MHz, Acetone-*d*₆) δ 155.52, 148.85, 138.62, 137.63, 136.38, 131.21, 130.21, 129.99, 129.55, 128.41, 127.19, 125.96, 123.86, 121.63, 118.39, 117.09, 114.50, 103.64, 51.50, 30.99, 30.50, 20.52, 14.10. HRMS (ESI) *m/z* calcd for C₂₃H₂₂N₃ [M+H]⁺: 340.1808, found: 340.1807.

1-butyl-3-(6-methylpyridin-2-yl)-4-(nitromethyl)-1,4-dihydroquinoline (6)

¹H NMR (400 MHz, Acetone-*d*₆) δ 7.42 (s, 1H), 7.39 (d, *J* = 7.7 Hz, 1H), 7.27 (d, *J* = 8.1 Hz, 1H), 7.15 – 7.04 (m, 2H), 6.96 (d, *J* = 8.1 Hz, 1H), 6.84 (dd, *J* = 7.4, 1.1 Hz, 1H), 6.80 (d, *J* = 7.6 Hz, 1H), 5.04 (dd, *J* = 8.6, 4.2 Hz, 1H), 4.61 (dd, *J* = 10.9, 4.1 Hz, 1H), 4.29 (dd, *J* = 10.9, 8.6 Hz, 1H), 3.82 (ddd, *J* = 14.2, 8.0, 5.8 Hz, 1H), 3.59 (ddd, *J* = 14.9, 8.3, 6.9 Hz, 1H), 2.35 (s, 3H), 1.68 – 1.52 (m, 2H), 1.38 – 1.26 (m, 2H), 0.85 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (126 MHz, Acetone-*d*₆) δ 158.09, 155.89, 150.29, 139.59, 138.35, 137.19, 135.90, 133.94, 130.59, 130.03, 129.55, 128.82, 127.80, 123.21, 122.83, 122.27, 119.55, 118.60,

114.62, 113.16, 105.69, 80.68, 51.02, 39.21, 30.90, 24.76, 20.66, 14.13. HRMS (ESI) m/z calcd for $C_{20}H_{24}N_3O_2$ $[M+H]^+$: 338.1863, found: 338.1855.

1-butyl-3-(3-chlorophenyl)-4-(nitromethyl)-1,4-dihydroquinoline (7)

1H NMR (400 MHz, Acetone- d_6) δ 7.45 (t, $J = 2.0$ Hz, 1H), 7.38 (ddd, $J = 8.0, 2.0, 1.0$ Hz, 1H), 7.21 (t, $J = 8.0$ Hz, 1H), 7.19 – 7.09 (m, 2H), 7.07 – 6.99 (m, 2H), 6.96 (d, $J = 8.0$ Hz, 1H), 6.83 (td, $J = 7.4, 1.1$ Hz, 1H), 4.80 (dd, $J = 8.9, 4.1$ Hz, 1H), 4.42 (dd, $J = 11.4, 4.1$ Hz, 1H), 4.20 (dd, $J = 11.4, 8.9$ Hz, 1H), 3.81 (ddd, $J = 14.3, 8.2, 5.8$ Hz, 1H), 3.61 (ddd, $J = 14.8, 8.4, 6.8$ Hz, 1H), 1.68 – 1.57 (m, 2H), 1.39 – 1.26 (m, 2H), 0.85 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (126 MHz, Acetone- d_6) δ 141.05, 139.52, 135.22, 134.30, 131.15, 129.85, 129.02, 125.70, 123.92, 122.65, 122.43, 121.45, 113.04, 103.73, 79.85, 50.82, 40.44, 30.88, 20.69, 14.13. HRMS (ESI) m/z calcd for $C_{20}H_{22}ClN_2O^{2+}$ $[M+H]^+$: 357.1364, found: 357.1369.

Series of quaternary quinolinium salts

1-butyl-[2,3-biquinolin]-1-ium bromide (2)— 1H NMR (400 MHz, Chloroform- d) δ 11.33 (d, $J = 1.9$ Hz, 1H), 10.20 (s, 0H), 9.15 (d, $J = 8.6$ Hz, 1H), 8.57 (dd, $J = 8.2, 1.4$ Hz, 1H), 8.46 (d, $J = 8.6$ Hz, 1H), 8.32 (d, $J = 8.9$ Hz, 1H), 8.25 – 8.13 (m, 2H), 7.97 (ddd, $J = 8.1, 7.0, 0.9$ Hz, 1H), 7.90 (d, $J = 6.7$ Hz, 0H), 7.81 (ddd, $J = 8.5, 6.8, 1.4$ Hz, 1H), 7.63 (ddd, $J = 8.1, 6.8, 1.2$ Hz, 1H), 5.68 (t, $J = 7.6$ Hz, 2H), 2.24 – 2.12 (m, 2H), 1.74 – 1.64 (m, 2H), 1.06 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (126 MHz, DMSO) δ 150.59, 148.87, 147.35, 144.11, 138.34, 137.17, 136.10, 132.31, 131.52, 130.91, 130.35, 129.65, 129.08, 128.17, 127.86, 127.65, 119.07, 118.87, 57.68, 31.69, 19.24, 13.50. HRMS (ESI) m/z calcd for $C_{22}H_{21}N^{2+}$ $[M]^+$: 313.1699, found: 313.1695.

1-(4-chlorobenzyl)-[2,3-biquinolin]-1-ium bromide (3)— 1H NMR (400 MHz, DMSO- d_6) δ 10.67 (d, $J = 2.1$ Hz, 1H), 10.24 (s, 1H), 8.79 (d, $J = 8.6$ Hz, 1H), 8.67 (d, $J = 7.8$ Hz, 1H), 8.58 (d, $J = 8.6$ Hz, 1H), 8.49 (d, $J = 8.9$ Hz, 1H), 8.30 – 8.20 (m, 2H), 8.16 (d, $J = 8.1$ Hz, 1H), 8.10 (t, $J = 7.6$ Hz, 1H), 7.95 (ddd, $J = 8.4, 6.8, 1.5$ Hz, 1H), 7.77 (t, $J = 7.6$ Hz, 1H), 7.62 – 7.43 (m, 3H), 6.60 (s, 2H). ^{13}C NMR (126 MHz, DMSO) δ 150.58, 150.05, 147.32, 144.94, 138.36, 137.18, 136.21, 133.39, 132.98, 132.64, 131.66, 130.94, 130.46, 129.86, 129.31, 129.06, 129.00, 128.19, 127.90, 127.69, 119.34, 118.93, 59.79. HRMS (ESI) m/z calcd for $C_{25}H_{18}ClN^{2+}$ $[M]^+$: 381.1153, found: 381.1158.

1-methyl-[2,3-biquinolin]-1-ium iodide (4)—Obtained as a yellow solid. 1H NMR (400 MHz, DMSO- d_6) δ 10.40 (s, 1H), 10.12 (s, 1H), 8.76 (d, $J = 8.6$ Hz, 1H), 8.62 (dd, $J = 12.2, 8.4$ Hz, 2H), 8.52 (d, $J = 8.8$ Hz, 1H), 8.36 (ddd, $J = 8.7, 7.0, 1.6$ Hz, 1H), 8.24 (d, $J = 8.5$ Hz, 1H), 8.15 (dt, $J = 7.8, 3.6$ Hz, 2H), 7.95 (ddd, $J = 8.6, 6.8, 1.6$ Hz, 1H), 7.76 (t, $J = 7.5$ Hz, 1H), 4.83 (s, 3H). HRMS (ESI) m/z calcd for $C_{19}H_{15}N^{2+}$ $[M]^+$: 271.1230, found: 271.1226.

1-nonylpyridin-1-ium bromide (17)— 1H NMR (500 MHz, Chloroform- d) δ 9.53 (d, $J = 5.6$ Hz, 2H), 8.54 (t, $J = 7.8$ Hz, 1H), 8.24 – 8.07 (m, 2H), 5.02 (t, $J = 7.5$ Hz, 2H), 2.05 (p, $J = 7.5$ Hz, 2H), 1.41 – 1.17 (m, 12H), 0.86 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (126 MHz, $CDCl_3$)

δ 145.16, 145.12, 128.46, 62.17, 32.06, 31.76, 29.29, 29.14, 29.06, 26.06, 22.61, 14.10.
HRMS (ESI) m/z calcd for $C_{14}H_{24}N^+$ [M]⁺: 206.1903, found: 206.1921

***N,N,N*-triethylnonan-1-aminium bromide (18)**—¹H NMR (400 MHz, DMSO-*d*₆) δ 3.23 (q, $J = 7.2$ Hz, 6H), 3.11 (dd, $J = 7.8, 4.1$ Hz, 2H), 1.65 – 1.49 (m, 2H), 1.34 – 1.23 (m, 12H), 1.20 – 1.14 (m, 9H), 0.92 – 0.81 (m, 3H). ¹³C NMR (126 MHz, DMSO) δ 55.94, 51.89, 45.65, 38.79, 38.66, 31.20, 28.76, 28.48, 25.76, 22.05, 20.87, 13.93, 7.12. HRMS (ESI) m/z calcd for $C_{15}H_{34}N^+$ [M]⁺: 228.2686, found: 228.2708.

1-*isopropyl*-[2,3-*biquinolin*]-1-ium iodide (19)—¹H NMR (400 MHz, DMSO-*d*₆) δ 10.19 (d, $J = 1.9$ Hz, 1H), 10.12 (d, $J = 1.7$ Hz, 1H), 8.82 (d, $J = 9.3$ Hz, 1H), 8.76 (d, $J = 8.6$ Hz, 1H), 8.66 (dd, $J = 8.3, 1.5$ Hz, 1H), 8.58 (d, $J = 8.6$ Hz, 1H), 8.36 (ddd, $J = 8.8, 7.1, 1.6$ Hz, 1H), 8.27 (d, $J = 8.5$ Hz, 1H), 8.19 – 8.10 (m, 3H), 7.94 (ddd, $J = 8.4, 6.9, 1.5$ Hz, 1H), 7.76 (ddd, $J = 8.1, 6.8, 1.2$ Hz, 1H), 6.08 – 5.95 (m, 1H), 1.89 (d, $J = 6.5$ Hz, 6H). ¹³C NMR (126 MHz, DMSO) δ 150.64, 147.30, 144.00, 138.30, 136.11, 132.32, 131.74, 130.84, 130.25, 129.73, 129.25, 128.67, 128.11, 127.87, 127.67, 119.03, 118.70, 21.94. HRMS (ESI) m/z calcd for $C_{21}H_{19}N^{2+}$ [M]⁺: 299.1543, found: 299.1542.

1-*propyl*-[2,3-*biquinolin*]-1-ium bromide (20)—¹H NMR (400 MHz, DMSO-*d*₆) δ 10.42 (d, $J = 2.0$ Hz, 1H), 10.14 (s, 1H), 8.77 (d, $J = 8.7$ Hz, 1H), 8.73 (d, $J = 8.9$ Hz, 1H), 8.66 (d, $J = 7.1$ Hz, 1H), 8.53 (d, $J = 8.7$ Hz, 1H), 8.34 (ddd, $J = 8.6, 6.9, 1.5$ Hz, 1H), 8.25 (d, $J = 8.4$ Hz, 1H), 8.14 (t, $J = 8.0$ Hz, 2H), 7.94 (ddd, $J = 8.5, 6.9, 1.5$ Hz, 1H), 7.76 (t, $J = 7.8$ Hz, 1H), 5.23 (t, $J = 7.7$ Hz, 2H), 2.12 (h, $J = 7.4$ Hz, 2H), 1.09 (t, $J = 7.3$ Hz, 3H). ¹³C NMR (126 MHz, DMSO) δ 150.60, 148.90, 147.35, 144.14, 138.35, 137.20, 136.07, 132.27, 131.51, 130.91, 130.36, 129.63, 129.08, 128.17, 127.86, 127.66, 119.10, 118.87, 59.03, 23.17, 10.63. HRMS (ESI) m/z calcd for $C_{21}H_{19}N^{2+}$ [M]⁺: 299.1543, found: 299.1542.

1-*hexyl*-[2,3-*biquinolin*]-1-ium bromide (21)—¹H NMR (500 MHz, DMSO-*d*₆) δ 10.41 (d, $J = 2.0$ Hz, 1H), 10.12 (s, 0H), 8.76 (d, $J = 8.6$ Hz, 1H), 8.70 (d, $J = 9.0$ Hz, 1H), 8.65 (d, $J = 8.0$ Hz, 1H), 8.52 (d, $J = 8.6$ Hz, 1H), 8.34 (ddd, $J = 8.8, 7.0, 1.5$ Hz, 1H), 8.24 (d, $J = 8.4$ Hz, 1H), 8.18 – 8.09 (m, 2H), 7.94 (ddd, $J = 8.4, 6.8, 1.5$ Hz, 1H), 7.76 (ddd, $J = 8.0, 6.7, 1.2$ Hz, 1H), 5.25 (t, $J = 7.9$ Hz, 2H), 2.07 (p, $J = 7.6$ Hz, 2H), 1.53 (p, $J = 7.3$ Hz, 2H), 1.42 – 1.27 (m, 6H), 0.90 (t, $J = 6.9$ Hz, 3H). ¹³C NMR (126 MHz, DMSO) δ 150.60, 148.90, 147.36, 144.11, 138.35, 137.16, 136.11, 132.31, 131.52, 130.92, 130.35, 129.64, 129.07, 128.18, 127.87, 127.66, 119.07, 118.88, 57.83, 30.71, 29.70, 25.46, 21.95, 13.86. HRMS (ESI) m/z calcd for $C_{24}H_{25}N^{2+}$ [M]⁺: 341.2012, found: 341.2013.

1-*nonyl*-[2,3-*biquinolin*]-1-ium bromide (22)—¹H NMR (400 MHz, DMSO-*d*₆) δ 10.42 (d, $J = 1.8$ Hz, 1H), 10.14 – 10.11 (d, $J = 1.54$ Hz, 1H), 8.77 (d, $J = 8.6$ Hz, 1H), 8.70 (d, $J = 9.0$ Hz, 1H), 8.66 (d, $J = 8.3$ Hz, 1H), 8.53 (d, $J = 8.7$ Hz, 1H), 8.34 (ddd, $J = 8.7, 7.0, 1.4$ Hz, 1H), 8.24 (d, $J = 8.5$ Hz, 1H), 8.14 (t, $J = 8.2$ Hz, 2H), 7.94 (ddd, $J = 8.4, 6.9, 1.4$ Hz, 1H), 7.76 (ddd, $J = 8.1, 7.0, 1.1$ Hz, 1H), 5.26 (t, $J = 7.8$ Hz, 2H), 2.08 (p, $J = 9.5, 8.6$ Hz, 2H), 1.51 (tt, $J = 9.7, 5.3$ Hz, 2H), 1.35 – 1.39 (m, 2H), 1.32 – 1.18 (m, 6H), 0.85 (t, $J = 7.1$ Hz, 3H). ¹³C NMR (126 MHz, DMSO) δ 150.59, 148.88, 147.35, 144.09, 138.34, 137.15, 136.09, 132.29, 131.51, 130.90, 130.34, 129.63, 129.06, 128.17, 127.86, 127.65,

119.08, 118.88, 57.81, 31.20, 29.70, 28.82, 28.52, 25.77, 22.04, 13.91. HRMS (ESI) m/z calcd for $C_{27}H_{31}N^{2+}$ $[M]^{+}$: 383.2482, found: 383.2464.

1-butyl-3-(naphthalen-2-yl)quinolin-1-ium bromide (23)— 1H NMR (500 MHz, DMSO- d_6) δ 10.18 (d, $J = 2.1$ Hz, 1H), 9.80 (d, $J = 1.9$ Hz, 1H), 8.66 (t, $J = 4.5$ Hz, 2H), 8.54 (d, $J = 6.6$ Hz, 0H), 8.29 (ddd, $J = 8.8, 7.0, 1.5$ Hz, 1H), 8.24 (d, $J = 8.7$ Hz, 1H), 8.19 (dd, $J = 8.5, 1.9$ Hz, 1H), 8.14 – 8.03 (m, 3H), 7.73 – 7.63 (m, 2H), 5.19 (t, $J = 7.8$ Hz, 2H), 2.07 (p, $J = 7.7$ Hz, 1H), 1.53 (h, $J = 7.4$ Hz, 2H), 0.99 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (126 MHz, DMSO) δ 148.82, 143.37, 136.27, 135.36, 133.52, 133.09, 132.98, 130.93, 130.80, 130.20, 129.82, 129.26, 128.38, 127.80, 127.54, 127.28, 127.07, 124.51, 118.86, 57.53, 31.69, 19.30, 13.51. HRMS (ESI) m/z calcd for $C_{23}H_{22}N^{+}$ $[M]^{+}$: 312.1747, found: 312.1754.

1-(pent-4-en-1-yl)-[2,3-biquinolin]-1'-ium bromide (24)—Obtained as a offwhite solid. 1H NMR (400 MHz, DMSO- d_6) δ 10.41 (d, $J = 2.0$ Hz, 1H), 10.17 – 10.11 (m, 1H), 8.77 (d, $J = 8.7$ Hz, 1H), 8.68 (dd, $J = 16.9, 8.6$ Hz, 2H), 8.53 (d, $J = 8.6$ Hz, 1H), 8.35 (t, $J = 7.8$ Hz, 1H), 8.25 (d, $J = 8.3$ Hz, 1H), 8.14 (t, $J = 7.7$ Hz, 3H), 7.95 (t, $J = 7.3$ Hz, 1H), 7.77 (dd, $J = 8.3, 6.9$ Hz, 1H), 6.05 – 5.78 (m, 1H), 5.27 (d, $J = 7.6$ Hz, 2H), 5.18 – 5.09 (m, 1H), 5.06 (d, $J = 10.8$ Hz, 1H), 2.35 – 2.28 (m, 2H), 2.25 – 2.14 (m, 2H). ^{13}C NMR (126 MHz, DMSO) δ 150.58, 149.21, 149.08, 147.35, 144.16, 138.35, 137.65, 137.18, 137.10, 136.13, 132.28, 131.54, 130.92, 130.36, 129.65, 129.10, 128.17, 127.95, 119.04, 118.85, 115.87, 57.46, 29.89, 28.52. HRMS (ESI) m/z calcd for $C_{23}H_{21}N^{2+}$ $[M]^{+}$: 325.1699, found: 325.1696.

Miscellaneous Scaffolds

1-butyl-4-phenyl-1,4-dihydro-2,3-biquinoline (8) ^{15}N — 1H NMR (400 MHz, Acetone- d_6) δ 8.22 (d, $J = 8.7$ Hz, 1H), 8.07 (dd, $J = 8.3, 1.0$ Hz, 1H), 8.04 (d, $J = 8.8$ Hz, 1H), 7.88 (dd, $J = 8.1, 1.6$ Hz, 1H), 7.74 (ddd, $J = 8.4, 6.9, 1.5$ Hz, 1H), 7.66 (s, 1H), 7.57 – 7.49 (m, 3H), 7.25 (dd, $J = 7.4, 1.6$ Hz, 1H), 7.21 – 7.07 (m, 4H), 6.72 – 6.63 (m, 2H), 6.57 (s, 1H), 3.55 – 3.45 (m, 1H), 3.43 – 3.28 (m, 1H), 1.78 – 1.63 (m, 1H), 1.62 – 1.49 (m, 1H), 1.44 (h, $J = 7.3$ Hz, 2H), 0.94 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (125 MHz, Acetone- d_6) δ 155.95, 148.44, 145.66, 144.60, 136.68, 134.47, 131.35, 130.33, 130.04, 129.76, 128.85, 128.40, 128.08, 128.00, 127.91, 127.15, 127.00, 122.76, 118.88, 116.96, 111.46, 62.76, 49.76, 20.85, 14.24. HRMS (ESI) m/z calcd for $C_{28}H_{27}N^{2+}$ $[M+H]^{+}$: 391.2169, found: 391.2187.

1-butyl-2-phenyl-1,2-dihydro-2,3-biquinoline (9) ^{15}N — 1H NMR (400 MHz, Acetone- d_6) δ 8.01 (d, $J = 8.5$ Hz, 1H), 7.95 – 7.87 (m, 2H), 7.78 – 7.72 (m, 2H), 7.62 (ddd, $J = 8.4, 6.9, 1.5$ Hz, 1H), 7.51 (dd, $J = 8.2, 1.4$ Hz, 2H), 7.42 – 7.31 (m, 2H), 7.21 – 7.08 (m, 4H), 7.06 – 6.97 (m, 1H), 6.94 (td, $J = 7.4, 1.2$ Hz, 1H), 5.90 (s, 1H), 4.12 – 3.99 (m, 1H), 3.87 (dt, $J = 14.8, 7.6$ Hz, 1H), 1.91 – 1.79 (m, 2H), 1.63 – 1.48 (m, 2H), 1.04 (t, $J = 7.4$ Hz, 3H). HRMS (ESI) m/z calcd for $C_{28}H_{27}N^{2+}$ $[M+H]^{+}$: 391.2169, found: 391.2187.

1-butyl-2-methyl-1,2-dihydro-2,3-biquinoline (10)—Synthesized using a reported procedure¹⁵ 1H NMR (400 MHz, Acetone- d_6) δ 8.14 (d, $J = 8.9$ Hz, 1H), 7.92 (d, $J = 8.8$ Hz,

1H), 7.87 (d, $J = 8.6$ Hz, 1H), 7.77 (d, $J = 6.7$ Hz, 1H), 7.60 (ddd, $J = 8.7, 7.2, 1.7$ Hz, 1H), 7.41 (ddd, $J = 8.6, 7.1, 1.1$ Hz, 1H), 7.36 (s, 1H), 7.08 – 6.96 (m, 2H), 6.57 (d, $J = 8.2$ Hz, 1H), 6.49 (td, $J = 7.3, 1.0$ Hz, 1H), 5.25 (q, $J = 6.2$ Hz, 1H), 3.54 – 3.43 (m, 1H), 3.29 – 3.11 (m, 1H), 1.63 – 1.53 (m, 2H), 1.38 – 1.27 (m, 2H), 1.06 (d, $J = 6.3$ Hz, 3H), 0.83 (t, $J = 7.4$ Hz, 3H). HRMS (ESI) m/z calcd for $C_{23}H_{24}N^{2+}$ $[M]^{+}$: 328.1939, found: 328.1873.

1-butyl-4-methyl-1,4-dihydro-2,3-biquinoline (11)— 1H NMR (400 MHz, Acetone- d_6) δ 7.92 (d, $J = 9.0$ Hz, 1H), 7.77 (dd, $J = 8.3, 1.0$ Hz, 1H), 7.69 – 7.61 (m, 2H), 7.50 (ddd, $J = 8.4, 6.9, 1.5$ Hz, 1H), 7.47 (s, 1H), 7.26 (ddd, $J = 8.1, 6.9, 1.2$ Hz, 1H), 7.15 (dd, $J = 7.4, 1.6$ Hz, 1H), 7.04 (ddd, $J = 8.6, 7.3, 1.6$ Hz, 1H), 6.91 – 6.80 (m, 2H), 4.52 (q, $J = 6.8$ Hz, 1H), 3.87 – 3.76 (m, 1H), 3.62 (ddd, $J = 14.8, 8.2, 7.0$ Hz, 1H), 1.72 – 1.56 (m, 2H), 1.40 – 1.29 (m, 2H), 1.15 (d, $J = 6.8$ Hz, 3H), 0.86 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (125 MHz, Acetone- d_6) δ 155.79, 148.80, 145.19, 136.74, 136.10, 130.87, 130.32, 130.12, 129.54, 128.46, 127.94, 126.91, 126.79, 123.49, 118.66, 116.98, 112.44, 54.67, 49.54, 30.92, 20.92, 17.54, 14.28. HRMS (ESI) m/z calcd for $C_{23}H_{25}N^{2+}$ $[M+H]^{+}$: 329.2012, found: 329.1991.

2-(1-butyl-1 *H*-indol-3-yl)quinoline (12)—Synthesized using a reported procedure¹⁶

1H NMR (400 MHz, Chloroform- d) δ 8.87 – 8.58 (m, 1H), 8.17 (dd, $J = 8.3, 1.1$ Hz, 1H), 8.14 (d, $J = 8.5$ Hz, 1H), 7.87 (s, 1H), 7.85 (d, $J = 8.6$ Hz, 1H), 7.79 (dd, $J = 8.1, 1.4$ Hz, 1H), 7.71 (ddd, $J = 8.4, 6.9, 1.5$ Hz, 1H), 7.51 – 7.47 (m, 1H), 7.47 – 7.41 (m, 1H), 7.37 – 7.31 (m, 2H), 4.24 (t, $J = 7.1$ Hz, 2H), 2.01 – 1.87 (m, 2H), 1.53 – 1.36 (m, 2H), 1.00 (t, $J = 7.4$ Hz, 3H). HRMS (ESI) m/z calcd for $C_{21}H_{21}N^{2+}$ $[M+H]^{+}$: 301.1699, found: 301.1704.

10-butylacridin-9(10*H*)-one (15)—Synthesized using reported procedure¹⁷

1H NMR (400 MHz, Chloroform- d) δ 8.61 (dd, $J = 8.0, 1.7$ Hz, 2H), 7.75 (ddd, $J = 8.7, 7.0, 1.7$ Hz, 2H), 7.52 (d, $J = 8.7$ Hz, 2H), 7.36 – 7.27 (m, 2H), 4.45 – 4.22 (m, 2H), 2.01 – 1.88 (m, 2H), 1.62 (h, $J = 7.4$ Hz, 2H), 1.11 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 177.98, 141.82, 133.85, 128.01, 122.52, 121.18, 114.55, 45.98, 29.23, 20.20, 13.86. HRMS (ESI) m/z calcd for $C_{17}H_{18}NO^{+}$ $[M+H]^{+}$: 252.1383, found: 252.1380.

Antibacterial activity

Bacterial strains, plasmids, and growth conditions—The bacterial strains and plasmids used in this study were described previously. Briefly, strain SME4382 carries a single-copy *virB-lacZ* reporter fusion in the chromosome and a plasmid pHG165*virF*, expressing VirF protein. A control strain SME3359 carries a *lacZ* reporter gene under the control of a synthetic promoter that is repressed by LacI, and a plasmid that expresses LacI protein. The bacterial cultures for *in vivo* dose-response assays were grown in 3-(*N*-morpholino)propanesulfonic acid (MOPS)-buffered minimal medium. Cultures for growth rate experiments were grown in tryptone-yeast extract (TY) broth (0.8% Difco tryptone, 0.5% Difco yeast extract, and 0.5% NaCl [pH 7.0]). Ampicillin (200 μ g/mL), and isopropyl- β -D-thiogalactopyranoside (IPTG) were added as indicated. All cultures were grown at 37°C with aeration, unless otherwise noted.

***In vivo* dose-response experiments**—Twenty-four commercially available compounds were obtained from Sigma Aldrich (St. Louis, MO). *In vivo* dose-response assays were performed as previously described.¹² In brief, each analogue was dissolved in 100% dimethyl sulfoxide (DMSO). Bacterial cultures of SME4382 and SME3359 were grown to an optical density at 600 nm (OD_{600}) of ~0.1 and then mixed with various concentrations of analogues (final concentration of DMSO, 6.2%), induced with 1 mM IPTG (final concentration) for 3 hours at 37°C, lysed, and β -galactosidase activity was measured. Uninduced (no IPTG and no analogues) and uninhibited (1 mM IPTG and no analogues) controls were included for each of the *virB-lacZ* and control strain, and used to normalize β -galactosidase activity, as described previously. Fifty percent inhibitory concentrations (IC_{50}) were calculated and graphs were drawn using Graphpad Prism (GraphPad, La Jolla, CA). All data plotted were from three independent experiments with two replicates in each experiment.

***E. coli* growth experiments**—To test whether the compounds in this study had any impact on the growth of the bacterial strains used for *in vivo* dose-response assays (SME4382 and SME3359), the growth rate in the presence and absence of the compounds were compared using a procedure described previously, except the bacterial cultures were grown in TY broth. Briefly, the cells were grown at 37°C in TY broth plus 1 mM IPTG (final concentration), in 24-well microtiter plate, either with compounds (44 μ M, 6.2% DMSO) or with DMSO (6.2%) alone, in a PowerWave XS plate reader (BioTek Instruments).

Stability Analysis—Compounds were dissolved at 10 μ M in PBS at pH 7.4 (1% DMSO) and incubated at room temperature with either no thiol source as a negative control, 50 μ M glutathione (GSH). The mixtures were sampled every hour for eight hours or every 8 hours for 48 hours and analyzed by RP HPLC/UV/HRMS. The analytical RP HPLC/UV/HRMS system utilized for the analysis was a Waters Acquity system with UV-detection and mass-detection (Waters LCT Premier). The analytical method conditions included a Waters Acquity HSS T3 C18 column (2.1 \times 50mm, 1.8 μ m) and elution with a linear gradient of 99% water to 100% CH_3CN at 0.6 mL/min flow rate. Peaks on the 214 nm chromatographs were integrated using the Waters OpenLynx software. Absolute areas under the curve were compared at each time point to determine relative percent compound remaining. The masses of potential adducts were searched for in the final samples to determine if any detectable adduct formed. All samples were prepared in duplicate. Ethacrynic acid, a known Michael acceptor, was used as a positive control and was tested in both PBS and PBS/acetonitrile (1/1).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Research reported in this publication was supported by two Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health (8P30GM103495 and

P30GM103326, SME) and the NIH University of Kansas Chemical Methodology and Library Development Center funded by the NIH Institute of General Medical Sciences (P50GM069663).

References and notes

1. Organization WH. Antimicrobial Resistance: Global Report on Surveillance. 2014; 2014:1–257. http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1.
2. (a) Davies J, Davies D. Origins and evolution of antibiotic resistance. *Microbiology and Molecular Biology Reviews*. 2010; 74(3):417–433. [PubMed: 20805405] (b) Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E. Tackling antibiotic resistance. *Nature Reviews Microbiology*. 2011; 9(12):894–896. (c) English BK, Gaur AH. The use and abuse of antibiotics and the development of antibiotic resistance. *Hot Topics in Infection and Immunity in Children VI*. 2010:73–82. Springer. (d) Madhavan H, Murali S. Mechanisms of Development of Antibiotic Resistance in Bacteria Among Clinical Specimens. *J Clin Biomed Sci*. 2011; 1(2):43. (e) Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. *New England Journal of Medicine*. 2013; 368(4):299–302. [PubMed: 23343059] (f) Andersson DI, Hughes D. Persistence of antibiotic resistance in bacterial populations. *FEMS microbiology reviews*. 2011; 35(5):901–911. [PubMed: 21707669] (g) Shlaes DM, Sahn D, Opiela C, Spellberg B. The FDA Reboot of Antibiotic Development. *Antimicrobial agents and chemotherapy*. 2013; 57(10):4605–4607. [PubMed: 23896479] (h) Jabes D. The antibiotic R&D pipeline: an update. *Current opinion in microbiology*. 2011; 14(5):564–569. [PubMed: 21873107]
3. Higgins D, Nazareno E, DiRita V. The virulence gene activator ToxT from *Vibrio cholerae* is a member of the AraC family of transcriptional activators. *Journal of bacteriology*. 1992; 174(21):6974–6980. [PubMed: 1400247]
4. Gómez-Duarte OG, Kaper JB. A plasmid-encoded regulatory region activates chromosomal *eaeA* expression in enteropathogenic *Escherichia coli*. *Infection and immunity*. 1995; 63(5):1767–1776. [PubMed: 7729884]
5. Hovey AK, Frank DW. Analyses of the DNA-binding and transcriptional activation properties of ExsA, the transcriptional activator of the *Pseudomonas aeruginosa* exoenzyme S regulon. *Journal of bacteriology*. 1995; 177(15):4427–4436. [PubMed: 7635828]
6. Egan SM. Growing repertoire of AraC/XylS activators. *Journal of bacteriology*. 2002; 184(20):5529–5532. [PubMed: 12270809]
7. Yang J, Tauschek M, Robins-Browne RM. Control of bacterial virulence by AraC-like regulators that respond to chemical signals. *Trends in microbiology*. 2011; 19(3):128–135. [PubMed: 21215638]
8. Garrity-Ryan LK, Kim OK, Balada-Llasat J-M, Bartlett VJ, Verma AK, Fisher ML, Castillo C, Songsunthong W, Tanaka SK, Levy SB. Small molecule inhibitors of LcrF, a *Yersinia pseudotuberculosis* transcription factor, attenuate virulence and limit infection in a murine pneumonia model. *Infection and immunity*. 2010; 78(11):4683–4690. [PubMed: 20823209]
9. Jennison AV, Verma NK. *Shigella flexneri* infection: pathogenesis and vaccine development. *FEMS microbiology reviews*. 2004; 28(1):43–58. [PubMed: 14975529]
10. Niyogi SK. Shigellosis. *Journal of microbiology (Seoul, Korea)*. 2005; 43(2):133–143.
11. Mounier J, Vasselon T, Hellio R, Lesourd M, Sansonetti P. *Shigella flexneri* enters human colonic Caco-2 epithelial cells through the basolateral pole. *Infection and immunity*. 1992; 60(1):237–248. [PubMed: 1729185]
12. (a) Koppolu V, Osaka I, Skredenske JM, Kettle B, Hefty PS, Li J, Egan SM. Small-Molecule Inhibitor of the *Shigella flexneri* Master Virulence Regulator VirF. *Infection and immunity*. 2013; 81(11):4220–4231. [PubMed: 24002059] (b) Skredenske JM, Koppolu V, Kolin A, Deng J, Kettle B, Taylor B, Egan SM. Identification of a Small-Molecule Inhibitor of Bacterial AraC Family Activators. *Journal of biomolecular screening*. 2013; 18(5):588–598. [PubMed: 23364515]
13. (a) Aksenov A, Nadein O, Borovlev I, Smushkevich YI. Investigations in the region of 2. 3'-biquinolyl 5. Investigation of the reaction of stabilized C-nucleophiles with 1-alkyl-3-(2-quinolyl)-quinolinium halides. *Chemistry of Heterocyclic Compounds*. 1998; 34(9):1045–1049. (b) Aksenov A. Investigations on 2. 3'-Biquinolyls. 15. Regioselectivity of the Addition of Nitromethane Anion

- to 1'-Alkyl-3'-(2-quinolyl) quinolinium Halides. *Chemistry of Heterocyclic Compounds*. 2003; 39(6):756–759.
14. (a) Renton-Harper P, Addy M, Moran J, Doherty F, Newcombe R. A comparison of chlorhexidine, cetylpyridinium chloride, triclosan, and C31G mouthrinse products for plaque inhibition. *Journal of periodontology*. 1996; 67(5):486–489. [PubMed: 8724706] (b) Bodor N, Buchwald P. Soft drug design: general principles and recent applications. *Medicinal research reviews*. 2000; 20(1):58–101. [PubMed: 10608921] (c) Bodor N, Kaminski JJ, Selk S. Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials. *Journal of medicinal chemistry*. 1980; 23(5):469–474. [PubMed: 7381846]
15. Aksenov AV, Nadein ON. Investigation of 2,3'-Biquinolyl. 10. The Regioselectivity of the Reaction of 2,3'-Biquinolyl and 1'-Alkyl-3-(2-quinolyl)quinolinium Halides with Halo Derivatives in the Presence of Metallic Lithium and Magnesium. *Chemistry of Heterocyclic Compounds*. 2000; 36(11):1314–1318.
16. Brasse M, Ellman JA, Bergman RG. A facile, metal- and solvent-free, autoxidative coupling of quinolines with indoles and pyrroles. *Chemical Communications*. 2011; 47(17):5019–5021. [PubMed: 21445416]
17. Garella D, Barge A, Upadhyaya D, Rodriguez Z, Palmisano G, Cravotto G. Fast, Solvent-Free, Microwave-Promoted Friedländer Annulation with a Reusable Solid Catalyst. *Synthetic Communications*. 2009; 40(1):120–128.




Figure 1.
In situ decomposition of **SE-1** to biquinolinium **2**.





**E1**VirF IC₅₀ = 7 μM**A2**VirF IC₅₀ = 10 μM**C4**VirF IC₅₀ = 11 μM

Figure 2.
Structures and VirF activator inhibition data for **E1** and **A2**.

**Scheme 1.**

Reagents and conditions: (a) $PdCl_2(PPh_3)_2$, K_2CO_3 , DMF/ H_2O , MW, $150\text{ }^\circ\text{C}$; (b) R_2Br , MW, $150\text{ }^\circ\text{C}$, 2h (c) $MeNO_2$, K_2CO_3 , H_2O , dioxane, rt, 4h.












Table 1



First round of synthetic analogues.

Entry	Structure	VirF IC ₅₀ (μM)	Control IC ₅₀ (μM)
SE-1/1	-	11	>100
2		11	>100
3		26	>100
4		10	>100
5		80	>100
6		>100	>100
7		>100	>100
8		No inhibition	No inhibition
9		>100	>100
10		No inhibition	No inhibition
11		>100	>100

Table 2

Data

Entry	Structure	VirF IC ₅₀ (μM)	Control Strain IC ₅₀ (μM)
12		No activity	No activity
13		No activity	No activity
14		8	15
15		No activity	No activity
16		No activity	No activity
17		>50	>50
18		No activity	No activity
19		12	>100
20		16	>100
21		11	>100
22		3	25

Entry	Structure	VirF IC ₅₀ (μM)	Control Strain IC ₅₀ (μM)
23		9	>100
24		11	>100